Literature DB >> 33242517

Associations of changes in fat free mass with risk for type 2 diabetes: Hispanic Community Health Study/Study of Latinos.

M N LeCroy1, S Hua2, R C Kaplan2, D Sotres-Alvarez3, Q Qi2, B Thyagarajan4, L C Gallo5, A Pirzada6, M L Daviglus6, N Schneiderman7, G A Talavera5, C R Isasi2.   

Abstract

AIMS: To determine whether loss of muscle mass (approximated using fat free mass [FFM]) is associated with risk for type 2 diabetes mellitus (T2DM) in Hispanic/Latino adults in the United States.
METHODS: Participants were Hispanic/Latino adults (18-74-year-olds) who completed Visit 2 of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL; multi-site, prospective cohort study; 6.1-year follow-up) and did not have T2DM at baseline (n = 6264). At baseline and Visit 2, FFM was measured using bioelectrical impedance analysis and fasting glucose, HbA1c, and fasting insulin were measured by examiners. Diabetes was defined according to American Diabetes Association criteria. Survey-weighted Poisson regression models examined the association of percent change in relative FFM (%ΔFFM) with incident prediabetes and T2DM. Survey-weighted multivariable regression models examined associations of %ΔFFM with changes in glucose and insulin measures.
RESULTS: Relative FFM declined by 2.1% between visits. %ΔFFM was inversely associated with incident prediabetes (p-for-trend = 0.001) and with changes in glucose and insulin measures (p-for-trend <0.0001). Findings were null, except for HOMA-IR, after adjustment for changes in adiposity measures. Associations were generally stronger for individuals with baseline overweight/obesity.
CONCLUSIONS: Reducing loss of FFM during adulthood may reduce prediabetes risk (primarily insulin resistance), particularly among individuals with overweight/obesity.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adiposity; Hispanic; Prospective studies; Sarcopenia; Type 2 diabetes

Mesh:

Year:  2020        PMID: 33242517      PMCID: PMC8425264          DOI: 10.1016/j.diabres.2020.108557

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  42 in total

1.  The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization.

Authors:  R A DeFronzo; E Jacot; E Jequier; E Maeder; J Wahren; J P Felber
Journal:  Diabetes       Date:  1981-12       Impact factor: 9.461

Review 2.  Insulin resistance and sarcopenia: mechanistic links between common co-morbidities.

Authors:  Mark E Cleasby; Pauline M Jamieson; Philip J Atherton
Journal:  J Endocrinol       Date:  2016-03-01       Impact factor: 4.286

3.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics".

Authors:  M Muscaritoli; S D Anker; J Argilés; Z Aversa; J M Bauer; G Biolo; Y Boirie; I Bosaeus; T Cederholm; P Costelli; K C Fearon; A Laviano; M Maggio; F Rossi Fanelli; S M Schneider; A Schols; C C Sieber
Journal:  Clin Nutr       Date:  2010-01-08       Impact factor: 7.324

4.  Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010.

Authors:  Seong-Su Moon
Journal:  Endocr J       Date:  2013-10-01       Impact factor: 2.349

5.  Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis.

Authors:  Dima Khadra; Leila Itani; Hana Tannir; Dima Kreidieh; Dana El Masri; Marwan El Ghoch
Journal:  World J Diabetes       Date:  2019-05-15

6.  The Role of Muscle Decline in Type 2 Diabetes Development: A 5-Year Prospective Observational Cohort Study.

Authors:  Katarzyna Maliszewska; Edyta Adamska-Patruno; Joanna Goscik; Danuta Lipinska; Anna Citko; Aleksandra Krahel; Katarzyna Miniewska; Joanna Fiedorczuk; Monika Moroz; Maria Gorska; Adam Kretowski
Journal:  Nutrients       Date:  2019-04-12       Impact factor: 5.717

7.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

Review 8.  Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.

Authors:  Ralph A DeFronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

9.  Insulin and extremity muscle mass in overweight and obese women.

Authors:  B Leon; S Jenkins; K Pepin; H Chaudhry; K Smith; G Zalos; B V Miller; K Y Chen; A T Remaley; M A Waclawiw; A E Sumner; R O Cannon
Journal:  Int J Obes (Lond)       Date:  2013-03-28       Impact factor: 5.095

10.  Relative muscle mass and the risk of incident type 2 diabetes: A cohort study.

Authors:  Sungwoo Hong; Yoosoo Chang; Hyun-Suk Jung; Kyung Eun Yun; Hocheol Shin; Seungho Ryu
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

View more
  3 in total

Review 1.  Bioelectrical Impedance Analysis for the Assessment of Body Composition in Sarcopenia and Type 2 Diabetes.

Authors:  Stefano Sbrignadello; Christian Göbl; Andrea Tura
Journal:  Nutrients       Date:  2022-04-29       Impact factor: 6.706

2.  Relationship of Fat Mass Index and Fat Free Mass Index With Body Mass Index and Association With Function, Cognition and Sarcopenia in Pre-Frail Older Adults.

Authors:  Reshma Aziz Merchant; Santhosh Seetharaman; Lydia Au; Michael Wai Kit Wong; Beatrix Ling Ling Wong; Li Feng Tan; Matthew Zhixuan Chen; Shu Ee Ng; John Tshon Yit Soong; Richard Jor Yeong Hui; Sing Cheer Kwek; John E Morley
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-24       Impact factor: 5.555

3.  Muscle strength and prediabetes progression and regression in middle-aged and older adults: a prospective cohort study.

Authors:  Shanhu Qiu; Xue Cai; Yang Yuan; Bo Xie; Zilin Sun; Duolao Wang; Tongzhi Wu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-01-23       Impact factor: 12.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.